Simulations Plus Launches Corporate Development Initiative
February 13 2024 - 9:15AM
Business Wire
Strategic investments in early-stage companies
to drive innovation and collaboration
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a
leading provider of modeling and simulation software and services
for pharmaceutical safety and efficacy, today provided additional
information on advancing its corporate allocation strategy,
specifically increased focus on strategic investments and
partnerships.
Simulations Plus will actively pursue investments and
partnerships in early-stage technology companies aimed at
accelerating software and services innovations, increasing
technology leadership in computational biology and chemistry,
expanding total market opportunity, and identifying potential
M&A candidates.
Key investment objectives include:
- Enhance Innovation and Adoption of Emerging
Technologies: Explore software and services innovation and seek
deeper visibility into evolving technologies, including artificial
intelligence-driven drug design (AIDD) and development.
- Grow M&A Pipeline: Seed investments and partnerships
in early-stage companies are expected to broaden the opportunity
pipeline and total addressable market (TAM).
- Expand Revenue Opportunities: Broaden portfolio
offerings through software technology and scientific service
partnerships and explore new partner revenue models.
- Drive Shareholder Returns: Optimize the combination of
organic growth, operating leverage, and strategic M&A to
deliver long-term sustainable returns to our stakeholders.
“Our team is very excited to launch this corporate development
initiative and formalize our corporate development programs with
the flexibility to make strategic investments and form joint
partnerships in early-stage companies,” said Will Frederick, Chief
Financial Officer and Chief Operating Officer. “Strategic
acquisitions to complement organic growth and expand TAM remain a
priority, and this corporate development initiative is designed to
allow us to reach into relevant technologies for immediate
competitive benefit and long-term support of future
acquisitions.”
Chief Executive Officer, Shawn O’Connor, added, “As leaders in
simulation software and consulting services, our research
scientists are uniquely qualified to identify promising new
technologies and services that can advance our growth objectives.
Many technologies used today were conceived and developed by
early-stage companies, and we believe that partnering and investing
in high-potential technologies will complement our R&D efforts
and keep Simulations Plus at the forefront of innovation.”
Interested parties can obtain more information here.
About Simulations Plus
Serving clients worldwide for more than 25 years, Simulations
Plus is a leading provider in the biosimulation market providing
software and consulting services supporting drug discovery,
development, research, and regulatory submissions. We offer
solutions that bridge artificial intelligence (AI)/machine
learning, physiologically based pharmacokinetics, quantitative
systems pharmacology/toxicology, and population PK/PD modeling
approaches. Our technology is licensed and applied by major
pharmaceutical, biotechnology, and regulatory agencies worldwide.
For more information, visit our website at
https://www.simulations-plus.com/. Follow us on LinkedIn | X |
YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our website to read
our 2023 ESG update.
Forward-Looking Statements
Except for historical information, the matters discussed in this
press release are forward-looking statements that involve risks and
uncertainties. Words like “believe,” “expect,” and “anticipate”
mean that these are our best estimates as of this writing, but
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to successfully integrate the Immunetrics
business with our own, as well as expenses we may incur in
connection therewith, our ability to maintain our competitive
advantages, acceptance of new software and improved versions of our
existing software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
market conditions, macroeconomic factors, and a sustainable market.
Further information on our risk factors is contained in our
quarterly and annual reports and filed with the U.S. Securities and
Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240213145849/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Lisa Fortuna
310-622-8251 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024